Use of a commercial line blot assay as a screening test for autoantibodies in inflammatory myopathies

Dalakas, 1991, Polymyositis, dermatomyositis and inclusion-body myositis, N Engl J Med, 325, 1487, 10.1056/NEJM199111213252107 Arnett, 1996, Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis, Arthritis Rheum, 39, 1507, 10.1002/art.1780390910 Shamim, 2000, Update on the genetics of the idiopathic inflammatory myopathies, Curr Opin Rheumatol, 12, 482, 10.1097/00002281-200011000-00002 Reichlin, 1984, Multiplicity of antibodies in myositis sera, Arthritis Rheum, 27, 1150, 10.1002/art.1780271011 Brouwer, 2001, Autoantibody profiles in the sera of European patients with myositis, Ann Rheum Dis, 60, 116, 10.1136/ard.60.2.116 Barbasso Helmers, 2007 Eloranta, 2007, A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies, Arthritis Rheum, 56, 3112, 10.1002/art.22860 Bohan, 1975, Polymyositis and dermatomyositis (first of two parts), N Engl J Med, 292, 344, 10.1056/NEJM197502132920706 Bohan, 1975, Polymyositis and dermatomyositis (second of two parts), N Engl J Med, 292, 403, 10.1056/NEJM197502202920807 Griggs, 1995, Inclusion body myositis and myopathies, Ann Neurol, 38, 705, 10.1002/ana.410380504 Love, 1991, A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups, Medicine (Baltimore), 70, 360, 10.1097/00005792-199111000-00002 Hengstman, 2006, Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen, Ann Rheum Dis, 65, 242, 10.1136/ard.2005.040717 Hengstman, 2006, Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy, Ann Rheum Dis, 65, 1635, 10.1136/ard.2006.052191 Ghirardello, 2006, Clinical implications of autoantibody screening in patients with autoimmune myositis, Autoimmunity, 39, 217, 10.1080/08916930600622645 Selva-O'Callaghan, 2006, Myositis-specific and myositis-associated antibodies in a series of eighty-eight Mediterranean patients with idiopathic inflammatory myopathy, Arthritis Rheum, 55, 791, 10.1002/art.22237 Targoff, 2006, A novel autoantibody to a 155-kd protein is associated with dermatomyositis, Arthritis Rheum, 54, 3682, 10.1002/art.22164 Betteridge, 2007, Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia, Rheumatology (Oxford), 46, 1005, 10.1093/rheumatology/kem045 Betteridge, 2007, Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis, Arthritis Rheum, 56, 3132, 10.1002/art.22862 Mahler, 2007, Novel aspects of autoantibodies to the PM/Scl complex: clinical, genetic and diagnostic insights, Autoimmun Rev, 6, 432, 10.1016/j.autrev.2007.01.013 Raijmakers, 2004, PM-Scl-75 is the main autoantigen in patients with the polymyositis/scleroderma overlap syndrome, Arthritis Rheum, 50, 565, 10.1002/art.20056 Espinosa, 2006, The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death, J Immunol, 176, 6277, 10.4049/jimmunol.176.10.6277 Rutjes, 1997, Anti-Ro52 antibodies frequently co-occur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy, Clin Exp Immunol, 109, 32, 10.1046/j.1365-2249.1997.4081308.x Greidinger, 2007, Differential tissue targeting of autoimmunity manifestations by autoantigen-associated Y RNAs, Arthritis Rheum, 56, 1589, 10.1002/art.22601 Briani, 2006, Update on idiopathic inflammatory myopathies, Autoimmunity, 39, 161, 10.1080/08916930600622132 Kubo, 1999, Prevalence and antigen specificity of anti-histone antibodies in patients with polymyositis/dermatomyositis, J Invest Dermatol, 112, 711, 10.1046/j.1523-1747.1999.00580.x Aloush, 2006, Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management, Semin Arthritis Rheum, 36, 4, 10.1016/j.semarthrit.2006.03.003